SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany

News Feed Item

Europe's First Healthcare Apps Summit to Include Speakers From the FDA and NHS

LONDON, January 30, 2014 /PRNewswire/ --

European Healthcare authorities FDA and NHS are due to speak at the first ever European Healthcare Apps Summit, an upcoming two-day event dedicated entirely to mobile apps in the pharmaceutical and healthcare industries

The meeting, hosted by Pharma IQ - a division of global events company IQPC - is the first of its kind in European grounds. A two-day event featuring a mix of innovative presentations and interactive breakout workgroups, the Healthcare Apps Summit allows Chief Technology Officers, Senior Designers, Digital Marketers and Enterprise Architects in the Healthcare and Pharma sectors a rare opportunity to network and discuss shared industry challenges as peers in order to achieve value in creating mobile apps.

Bakul Patel, Senior Policy Advisor to the Center Director, Center for Devices and Radiol FDA; Inderjit Singh, Head of Enterprise Architecture, NHS England; Julian Hitchcock, Counsel Lawford Davies Denoon and John Gerow Europe Director, Multichannel Marketing, AstraZeneca along with many other professionals in the field are among the expert speaker panel leading  this unique Summit. Topics to be covered include regulations and guidance on healthcare mobile apps, engaging end users, ensuring apps ROI, interoperability, data protection, risk management and more.

The Healthcare Apps Summit takes place on 28th - 30th April 2014 in London, UK. Find the draft program, event details and registration information about the summit on, phone +44(0)20-7036-1300 or email [email protected]

Media contact: Veronica Araujo, +44(0)20-7368-9748, [email protected] or visit

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Veronica Araujo [email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.